Brain infusion trial hopes to restore movement in chronic stroke patients

NCT ID NCT07318714

Recruiting now Disease control Sponsor: Astellas Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests a new drug called ASP2246 for adults who have trouble moving after a stroke. In the first part, small groups get increasing doses via brain surgery to check safety. In the second part, some get the drug and others get a sham surgery, with neither patient nor doctor knowing who got what. All participants then do physical therapy for 12 weeks and are followed for a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASP2246
What this could lead to: If successful, this could point toward a new treatment to improve movement after a stroke.
What could go wrong: This is a very early first-in-human trial with only 84 participants. The brain surgery carries risks like bleeding or infection, and the treatment may not improve function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral infarction ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC ISCHEMIC STROKE

Contacts and locations

Locations

Juntendo University Hospital
RECRUITING

Bunkyo-ku, Tokyo, Japan
Kyoto University Hospital
RECRUITING

Kyoto, Japan
Tohoku University Hospital
RECRUITING

Sendai, Miyagi, Japan
Tokushima University Hospital
RECRUITING

Tokushima, Japan
Toyama University Hospital
RECRUITING

Toyama, Toyama, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.